Constrictive Pericarditis or Cardiac Amyloidosis: Treating While Still Diagnosing
His echocardiogram fits constrictive pericarditis, but two exam clues point toward amyloidosis instead — a distinction that changes not just the diagnosis but how much a delay actually costs him.
D.K., a 71-year-old man, has spent most of the last two months more short of breath on the stairs to his apartment than he can remember being at any point since he stopped delivering mail on foot. He is otherwise a man who has aged into hypertension and little else — no diabetes, no prior cardiac diagnosis beyond an episode of pericarditis eight months ago that resolved, he was told, on its own. What brought him in this week wasn't the breathlessness alone; his ankles have been swelling by evening for the past three weeks, and his primary care physician noted a liver edge she hadn't felt on his exam a year ago.
The findings since admission point toward the right side of the heart struggling to fill, not to pump: elevated jugular venous pressure, hepatomegaly, and an echocardiogram showing septal bounce and respirophasic mitral inflow variation — patterns that argue for constrictive pericarditis, plausibly a late consequence of his pericarditis eight months ago, but that overlap substantially with restrictive cardiomyopathy on imaging alone. Two details complicate a clean read toward constriction: he has a history of bilateral carpal tunnel release surgery in his sixties, and his urinalysis this admission shows trace proteinuria. Neither finding proves anything on its own, but both are recognized early clues to cardiac amyloidosis, a restrictive process that constriction is not — and they do not point to the same kind of it. Bilateral carpal tunnel release years before any cardiac symptom is the classic herald of transthyretin amyloidosis; proteinuria points instead toward light-chain (AL) amyloidosis, a plasma-cell disease with entirely different treatment and a far shorter untreated survival. The distinction is not academic. Constrictive pericarditis from his prior episode could plausibly resolve with anti-inflammatory therapy alone; amyloidosis has its own specific treatment, and that treatment works better started earlier rather than after further decline.
On the wards, weighing two diagnoses at once
He has a well-documented pericarditis eight months ago and an echo pattern that fits constriction reasonably well. Post-inflammatory constrictive pericarditis is a recognized entity, and a meaningful fraction of cases in that transient phase resolve with a course of anti-inflammatory therapy rather than needing pericardiectomy at all. I'd rather try that first than send him through an amyloid workup that may turn out to be unnecessary.
If he had no pericarditis history at all, I wouldn't be proposing an empiric trial — I'd want a definitive answer before treating anything. The argument here rests specifically on having a plausible inciting event already on the record.
I don't think the carpal tunnel history and the proteinuria are things we can set aside while an anti-inflammatory trial plays out over several weeks. If this turns out to be transthyretin amyloidosis, tafamidis works by stabilizing the transthyretin tetramer before further deposition — it doesn't reverse existing infiltration, which means its actual benefit is largest the earlier it starts. A diagnostic delay here isn't neutral the way it might be for two conditions with similar treatment urgency; it has a real cost specifically if the amyloid reading turns out to be correct.
I'm not arguing against the anti-inflammatory trial itself — only against running it in isolation, as a first step that has to fail before we consider amyloid. The two workups don't actually conflict; a cardiac MRI and a technetium pyrophosphate scan can proceed on their own timeline while he's on colchicine, rather than one waiting on the other. One thing that does have to be sequenced, though: serum and urine immunofixation and serum free light chains get drawn alongside the scan, not after it. Somewhere between 10 and 30 percent of light-chain amyloid cases take up the bone tracer too, so a positive pyrophosphate scan means transthyretin disease only once a monoclonal protein has been excluded — and his proteinuria is exactly the finding that makes that exclusion non-optional here.
From where I sit, the practical case for doing both at once is straightforward. He's already declined enough to need admission, the imaging workup doesn't require holding anything, and if we wait to see whether the anti-inflammatory trial works before scanning for amyloid, we've built in exactly the delay that concerns me most about this getting to him too late. I'd start colchicine now, order the MRI, the PYP scan, and the light-chain studies together this admission rather than as outpatient follow-up, and let the actual results — not the sequence we happened to try things in — decide what happens next.
Agreed: colchicine started this admission, furosemide for his congestive symptoms, and both the cardiac MRI and technetium pyrophosphate scan ordered now rather than held for outpatient follow-up or gated behind the medical trial's result.
Not agreed, and the real open question once results return:
The anti-inflammatory trial continues on a defined timeline, with pericardiectomy referral reserved for failure to improve.
The colchicine trial stops being relevant, and tafamidis initiation becomes the priority regardless of how the constriction question resolves. If a monoclonal protein turns up instead, this becomes a hematology problem — tissue confirmation and plasma-cell-directed therapy, not tafamidis.
Cardiology will reassess in two weeks once both scans are back, not on a fixed anti-inflammatory-trial schedule.